Why ImmunityBio, Inc. (IBRX) stock moved
ImmunityBio, Inc. (IBRX) shares climbed 6.1% to $10.51 as of October 9, 2026, a significant gain from the prior close of $9.91. BestStocks flagged the session as a major change for IBRX. Below, we break down what changed for IBRX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
IBRX climbed 6.1% to $10.51
ImmunityBio announced participation in the Piper Sandler Virtual Oncology Symposium, with Founder and Executive Chairman Dr. Patrick Soon-Shiong scheduled to present (Business Wire, 2026-10-08). The stock rose 5.40% to $10.45 on volume of 7.9M shares (1.63x historical average for this time of day), suggesting investor interest in the company's clinical or commercial updates ahead of the event. ImmunityBio's presentation at the Piper Sandler Virtual Oncology Symposium for any updates on clinical programs or commercial traction; earnings report on 2026-11-03.
What it means for ImmunityBio, Inc. investors
For ImmunityBio, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 6.1% price move with conviction. Weighing against that: ImmunityBio, Inc. (IBRX) moved -6.94% from $8.07 to $7.51 on 2026-07-22; ImmunityBio, Inc. (IBRX) moved -5.23% from $8.22 to $7.79 on 2026-07-13. Wall Street's consensus price target sits at $12.00, implying +14.2% upside from $10.51. BestStocks rates the overall signal quality medium (64/100). With earnings roughly 25 days out, the next report is the most likely near-term test of the move.
IBRX price reaction
IBRX last traded at $10.51, up $0.60 (+6.05%) from the previous close of $9.91. The session traded on 1.7× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $7.72 and $10.51, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on ImmunityBio, Inc. (IBRX)
The consensus analyst price target on ImmunityBio, Inc. (IBRX) is $12.00, 14.2% above the recent $10.51. Here is how the bullish and bearish cases on IBRX line up.
The bullish case
- Wall Street's consensus price target of $12.00 implies +14.2% upside from $10.51.
- The Street's most bullish target is $12.00 (+14.2%).
- Material positive event.
- Strong 6.1% price move with conviction.
- Positive price momentum.
The bearish case
- ImmunityBio, Inc. (IBRX) moved -6.94% from $8.07 to $7.51 on 2026-07-22.
- ImmunityBio fell 8.23% to $8.14 as part of a broader biotech sector selloff on Friday, July 10.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 9, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for IBRX
Frequently asked questions about IBRX
Why did ImmunityBio, Inc. (IBRX) stock move?
IBRX climbed 6.1% to $10.51. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did IBRX stock rise?
IBRX gained 6.05% ($0.60) versus the prior close of $9.91, last trading at $10.51 on 1.7× average volume.
When is ImmunityBio, Inc.'s next earnings date?
IBRX's next earnings report is estimated for 2026-11-03 — about 25 days away.
What is the analyst price target for IBRX?
The consensus analyst price target for IBRX is $12.00, about 14.2% above the current $10.51. Over the past 90 days, analysts recorded 0 upgrades, 0 maintains, and 0 downgrades.
How BestStocks tracks IBRX
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared IBRX-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for IBRX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 9, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.